Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in the Management of Pelvic Tumors
share announcement

Advances in the Management of Pelvic Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 25 September 2024 | Viewed by 2566

Special Issue Editors

Dr. Maria Chiara Sighinolfi

E-Mail Website
Guest Editor
Urology Unit, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Milano, Italy
Interests: urology; oncology; robotic surgery
Dr. Giorgia Gaia

E-Mail Website
Guest Editor
Gynecology Unit, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Milano, Italy
Interests: ovarian cancer; uterine cancer; robotic and laparoscopic surgery; oncology

Special Issue Information

Dear Colleagues,

Pelvic tumors are quite frequent diseases and include prostate, bladder, uterine, ovarian, rectal and anal malignancies. The treatment of tumors occurring within the pelvis may be challenging.

This Special Issue will cover advances in the management of pelvic cancers, including surgical, medical and radiation treatments. It will focus on organ-confined and locally advanced diseases. Novel findings in robotic surgery as well as medical and personalized therapies are welcomed.

Dr. Maria Chiara Sighinolfi
Dr. Giorgia Gaia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pelvic cancer
  • prostate cancer
  • bladder cancer
  • uterine cancer
  • ovarian cancer
  • rectal cancer
  • anal cancer

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1842 KiB  
Article
Peritoneal Flap Following Lymph Node Dissection in Robotic Radical Prostatectomy: A Novel “Bunching” Technique
by Ahmed Gamal, Marcio Covas Moschovas, Abdel Rahman Jaber, Shady Saikali, Marco Sandri, Ela Patel, Evan Patel, Travis Rogers and Vipul Patel
Cancers 2024, 16(8), 1547; https://doi.org/10.3390/cancers16081547 - 18 Apr 2024
Viewed by 719
Abstract
Background: Pelvic lymph node dissection (PLND) is recommended while performing robot-assisted radical prostatectomy (RARP) for patients with localized intermediate or high-risk prostate cancer. However, symptomatic lymphoceles can occur after surgery, adding significant morbidity to patients. Our objective is to describe a novel Peritoneal [...] Read more.
Background: Pelvic lymph node dissection (PLND) is recommended while performing robot-assisted radical prostatectomy (RARP) for patients with localized intermediate or high-risk prostate cancer. However, symptomatic lymphoceles can occur after surgery, adding significant morbidity to patients. Our objective is to describe a novel Peritoneal Bladder Flap Bunching technique (PBFB) to reduce the risk of clinically significant lymphoceles in patients undergoing RARP and PLND. Methods: We evaluated 2267 patients who underwent RARP with PLND, dividing them into two groups: Group 1, comprising 567 patients who had the peritoneal flap (PBFB), and Group 2, comprising 1700 patients without the flap; propensity score matching carried out at a 1:3 ratio. Variables analyzed included estimated blood loss (EBL), operative time, postoperative complications, lymphocele formation, and the development of symptomatic lymphocele. Results: The two groups exhibited similar preoperative characteristics after matching. There was no statistically significant difference in the occurrence of lymphoceles between the flap group and the non-flap group, with rates of 24% and 20.9%, respectively (p = 0.14). However, none of the patients in the flap group (0%) developed symptomatic lymphoceles, whereas 2.2% of patients in the non-flap group experienced symptomatic lymphoceles (p = 0.01). Conclusion: We have demonstrated a modified technique for a peritoneal flap (PBFB) with the initial elimination of postoperative symptomatic lymphoceles and promising short-term outcomes. Full article
(This article belongs to the Special Issue Advances in the Management of Pelvic Tumors)
►▼ Show Figures

Figure 1

11 pages, 245 KiB  
Article
Open versus Robot-Assisted Radical Cystectomy for the Treatment of pT4a Bladder Cancer: Comparison of Perioperative Outcomes
by Davide Perri, Bernardo Rocco, Maria Chiara Sighinolfi, Pierluigi Bove, Antonio L. Pastore, Alessandro Volpe, Andrea Minervini, Alessandro Antonelli, Stefano Zaramella, Antonio Galfano, Giovanni E. Cacciamani, Antonio Celia, Orietta Dalpiaz, Simone Crivellaro, Francesco Greco, Giovannalberto Pini, Angelo Porreca, Andrea Pacchetti, Tommaso Calcagnile, Lorenzo Berti, Carlo Buizza, Federica Mazzoleni and Giorgio Bozziniadd Show full author list remove Hide full author list
Cancers 2024, 16(7), 1329; https://doi.org/10.3390/cancers16071329 - 28 Mar 2024
Viewed by 449
Abstract
We compared the perioperative outcomes of open (ORC) vs. robot-assisted (RARC) radical cystectomy in the treatment of pT4a MIBC. In total, 212 patients underwent ORC (102 patients, Group A) vs. RARC (110 patients, Group B) for pT4a bladder cancer. Patients were prospectively followed [...] Read more.
We compared the perioperative outcomes of open (ORC) vs. robot-assisted (RARC) radical cystectomy in the treatment of pT4a MIBC. In total, 212 patients underwent ORC (102 patients, Group A) vs. RARC (110 patients, Group B) for pT4a bladder cancer. Patients were prospectively followed and retrospectively reviewed. We assessed operative time, estimated blood loss (EBL), intraoperative and postoperative complications, length of stay, transfusion rate, and oncological outcomes. Preoperative features were comparable. The mean operative time was 232.8 vs. 189.2 min (p = 0.04), and mean EBL was 832.8 vs. 523.7 mL in Group A vs. B (p = 0.04). An intraoperative transfusion was performed in 32 (31.4%) vs. 11 (10.0%) cases during ORC vs. RARC (p = 0.03). The intraoperative complications rate was comparable. The mean length of stay was shorter after RARC (12.6 vs. 7.2 days, p = 0.02). Postoperative transfusions were performed in 36 (35.3%) vs. 13 (11.8%) cases (p = 0.03), and postoperative complications occurred in 37 (36.3%) vs. 29 (26.4%) patients in Groups A vs. B (p = 0.05). The positive surgical margin (PSM) rate was lower after RARC. No differences were recorded according to the oncological outcomes. ORC and RARC are feasible treatments for the management of pT4a bladder tumors. Minimally invasive surgery provides shorter operative time, bleeding, transfusion rate, postoperative complications, length of stay, and PSM rate. Full article
(This article belongs to the Special Issue Advances in the Management of Pelvic Tumors)
13 pages, 1650 KiB  
Article
Pelvic Exenteration for Recurrent Endometrial Cancer: A 15-Year Monocentric Retrospective Study
by Nando Fix, Sabrina Classen-von Spee, Saher Baransi, Verónica Luengas-Würzinger, Friederike Rawert, Ruth Lippert, Peter Mallmann and Björn Lampe
Cancers 2023, 15(19), 4725; https://doi.org/10.3390/cancers15194725 - 26 Sep 2023
Viewed by 805
Abstract
Treatment options for recurrent endometrial adenocarcinoma are limited. In those cases, secondary surgical procedures such as pelvic exenteration form the only possible curative approach. The aim of this study was analyzing the outcomes of patients who underwent pelvic exenteration during the treatment of [...] Read more.
Treatment options for recurrent endometrial adenocarcinoma are limited. In those cases, secondary surgical procedures such as pelvic exenteration form the only possible curative approach. The aim of this study was analyzing the outcomes of patients who underwent pelvic exenteration during the treatment of recurrent endometrial cancer intending to identify prognostic factors. More than 300 pelvic exenterations were performed. Fifteen patients were selected that received pelvic exenteration for recurrent endometrial adenocarcinoma. Data regarding patient characteristics, indication for surgery, complete cytoreduction, tumor grading and p53- and L1CAM-expression were collected and statistically evaluated. Univariate Cox regression was performed to identify predictive factors for long-term survival. The mean survival after pelvic exenteration for the whole patient population was 22.7 months, with the longest survival reaching up to 69 months. Overall survival was significantly longer for patients with a curative treatment intention (p = 0.015) and for patients with a well or moderately differentiated adenocarcinoma (p = 0.014). Complete cytoreduction seemed favorable with a mean survival of 32 months in contrast to 10 months when complete cytoreduction was not achieved. Pelvic exenteration is a possible treatment option for a selected group of patients resulting in a mean survival of nearly two years, offering a substantial prognostic improvement. Full article
(This article belongs to the Special Issue Advances in the Management of Pelvic Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop